Human papillomavirus disease and vaccines in adolescents

Adolescent Medicine: State of the Art Reviews

Volumn 21, Issue 2, 2010, Pages 347-363

  Moscicki, Anna Barbara ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862834687     PISSN: 19344287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5);525-541 (Pubitemid 43736116)
2. Durst M, Kleinheinz A, Hotz M, Gissman L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol. 1985;66(7): 1515-1522 (Pubitemid 15070392)
3. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16);2114-2119 (Pubitemid 34437346)
4. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:S16-S22
5. Woodworm CD. HPV Innate Immunity. Front Biosci. 2002;7(7);d2058-d2071
6. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer. 2009;19(4):508-512
7. Moiling JW, de Gruijl TD, Glim J, et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer. 2007;121(8): 1749-1755 (Pubitemid 47417293)
8. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384(2):410-414
9. Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Ped Adolesc Med. 2000;154:127-134 (Pubitemid 30075192)
10. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23); 2995-3002 (Pubitemid 32550118)
11. Moscicki AB, Palefsky J, Gonzales J, Schoolnik G. Human papillomavirus infection in sexually active adolescent females: Prevalence and risk factors. Pediatr Res. 1990;28:507-513 (Pubitemid 20366699)
12. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3);218-226 (Pubitemid 36152435)
13. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191(2);182-192 (Pubitemid 40096375)
14. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12):2077-2087 (Pubitemid 39636354)
15. Evander M, Edlund K, Gustaffson A, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 1995;171:1026-1030
16. Ho GY, Bierman R, Beardsley L, Chang CI, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428 (Pubitemid 28135669)
17. Moscicki AB, Ellenberg JH, Fahrat S, Xu J. HPV persistence in HIV infected and uninfected adolescent girls: risk factors and differences by phylogenetic types. J Infect Dis. 2004;190(1):37-45
18. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284 (Pubitemid 28125180)
19. Mount SL, Papillo JL. A Study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics. 1999;103(3):539-546
20. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001 ;357(9271); 1831-1836 (Pubitemid 32539115)
21. International Collaboration. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885-891
22. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609-1621
23. Modiano JF, Kokai Y, Weiner DB, Pykett MJ, Nowell PC, Lyttle CR. Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. J Cell Biochem. 1991;45(2):196-206
24. Ruutu M, Wahlroos N, Syrjanen K, Johansson B, Syrjanen S. Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E67E7 oncogenes in CaSki and SiHa cell Unes. Int J Gynecol Cancer. 2006; 16(3); 1261-1268 (Pubitemid 43886755)
25. Burchell A, Winer R, de Sanjose S, Franco E. Epidemiolgy and transmission dynamics of genital human papillomavirus infection. Vaccine Monographs. 2006;24(Suppl 3):52-62
26. De Sanjose S. La investigacion sobre la infeccion por virus del papiloma human y el cancer de cuello uterino en Espana. In: de Sanjose S, Garcia A, eds. El Virus del papiloma human y cancer: Epidemiologia y Prevencion. Madrid: EMISA; 2006
27. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119(11):2677-2684 (Pubitemid 44691325)
28. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 LI virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931-4939 (Pubitemid 46843434)
29. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5(10)
30. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314
31. Green J, Berrington de Gonzalez A, Sweetland S, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer. 2003;89(11);2078-2086 (Pubitemid 38030906)
32. Herrero R, Brinton LA, Reeves WC, et al. Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. Cancer. 1990;65(2):380-386 (Pubitemid 20035371)
33. Sierra-Torres CH, Tyring SK, Au WW. Risk contribution of sexual behavior and cigarette smoking to cervical neoplasia. Int J Gynecol Cancer. 2003;13(5);617-625 (Pubitemid 38222603)
34. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1060-1069
35. Moscicki AB, Singer A. The cervical epithelium during puberty and adolescence. In: Jordan JA, Singer A, eds. The Cervix: 2nd ed. Maiden: Blackwell; 2006:81-101
36. Castle PE, Jeronimo J, Schiffman M, et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res. 2006;66(2);1218-1224 (Pubitemid 43165993)
37. Moscicki AB, Grubbs-Burt V, Kanowitz S, Darragh T, Shiboski S. The significance of squamous metaplasia in the development of low grade squamous intra-epithelial lesions in young women. Cancer. 1999;85:1139-1144 (Pubitemid 29115594)
38. Hwang LY, Ma Y, Benningfield SM, et al. Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health. 2009;44(2): 103-110
39. Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113(10 Suppl):2841-2854
40. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol. 2003;102(4);765-773 (Pubitemid 37206413)
41. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968
42. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8(5):755-763 (Pubitemid 27404646)
43. Bamholtz-Sloan J, Patel N, Rollison D, Kortepeter K, Mackinnon J, Giuliano A. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control. 2009;20(7): 1129-1138
44. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11): 1582-1589 (Pubitemid 46799215)
45. Heatley MK. How should we grade ON? Histopathology. 2002;40(4):377-390
46. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007;197(2):e141-e146
47. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18-25
48. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127(5):805-815
49. Moscicki AB, Ma Y, Wibbelsman C, et al. Risks for cervical intraepithelial neoplasia 3 among adolescents and young women with abnormal cytology. Obstet Gynecol. 2008; 112(6): 1335-1342
50. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5);731-738 (Pubitemid 40271061)
51. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14(1):73-80
52. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6);342-362 (Pubitemid 35446606)
53. American College of Obstetricians and Gynecologists. ACOG Guidelines for Women's Health Care. Washington, DC: The American College of Obstetricians and Gynecologists; 2007.
54. American Society for Colposcopy and Cervical Pathology. Available at: www.asccp.org. Accessed June 26, 2010
55. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509);489-498 (Pubitemid 43208905)
56. Norman JE. Preterm labour. Cervical function and prematurity. Best Pract Res Clin Obstet Gynaecol. 2007;21(5):791-806 (Pubitemid 47543540)
57. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100-2106 (Pubitemid 38580153)
58. Samson S-L, Bentley JR, Fahey TJ, McKay DJ, Gil GH. The effect of loop electrosurgical excision. Obstet Gynecol. 2005;105:325-332
59. Coeshott CM, Smithson SL, Verderber E, et al. Pluronic F127-based systemic vaccine delivery systems. Vaccine. 2004;22(19):2396-2405 (Pubitemid 38757336)
60. Pinto LA, Castle PE, Roden RB, et al. HPV-16 LI VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine. 2005;23(27):3555-3564 (Pubitemid 40602790)
61. Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)-16 LI in healthy volunteers immunized with recombinant HPV-16 LI virus-like particles. J Infect Dis. 2003;188(2):327-338 (Pubitemid 36898167)
62. Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol. 2004;16(5):485-491 (Pubitemid 39159179)
63. Schiller JT, Nardelli-Haefliger D. Chapter 17: Second generation HPV vaccines to prevent cervical cancer. Vaccine. 2006;24 Suppl 3:S147-S153 (Pubitemid 44293037)
64. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21);1645-1651 (Pubitemid 35340782)
65. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107(1); 18-27
66. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) LI virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278 (Pubitemid 40590263)
67. Emeny RT, Wheeler CM, Jansen KU, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol. 2002;76(15):7832-7842 (Pubitemid 34761005)
68. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943 (Pubitemid 46740303)
69. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19): 1915-1927
70. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6711/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa). 2009;2(10):868-878
71. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent LI virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-2170 (Pubitemid 46977438)
72. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007; 25(21):4324-4333 (Pubitemid 46635934)
73. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data. 2005;362:1-55
74. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009;200(7): 1059-1067
75. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7-28 (Pubitemid 46148088)
76. Dempsey AF, Gebremariam A, Koutsky LA, Manhart L. Using risk factors to predict human papillomavirus infection: implications for targeted vaccination strategies in young adult women. Vaccine. 2008;26(8):1111-1117
77. Daling JR, Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. IARC Sci Publ. 1992(119):223-241
78. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-1510
79. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine. 2006;24 Suppl 3:S140-S146 (Pubitemid 44293032)
80. Goodman MT, Shvetsov YB, McDuffie K, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis. 2008;197(7):957-966 (Pubitemid 351590023)
81. Moscicki AB, Durako SJ, Houser J, et al. Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents. AIDS. 2003;17(3);311-320 (Pubitemid 36223255)
82. American Cancer Society. Cancer facts and figures, 2008. Atlanta, GA: American Cancer Society; 2008
83. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6(1):21-31 (Pubitemid 41831374)
84. Melbye M, Smith E, Wohlfahrt J, et al. Anal and cervical abnormality in women-prediction by human papillomavirus. Int J Cancer. 1996;68:559-564
85. Ogunbiyi OA, Scholefield JH, Robertson G, Smith JH, Sharp F, Rogers K. Anal human papillomavirus infection and squamous neoplasia in patients with invasive vulvar cancer. Obstet Gynecol. 1994;83(2):212-216 (Pubitemid 24043290)
86. Park IU, Ogilvie JW Jr, Anderson KE, et al. Anal human papillomavirus infection and abnormal anal cytology in women with genital neoplasia. Gynecol Oncol. 2009;114(3):399-403
87. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26 Suppl 10:K17-K28
88. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475 (Pubitemid 40270113)
89. Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010;39(1):166-181
90. Kreimer AR, Bhatia RK, Messeguer AL, Gonzalez P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis. 2010;37(6):386-391
91. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis. 2006;194(8):1044-1057 (Pubitemid 44547644)
92. Palefsky JM, Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am. 2009;36(1): 187-200
93. de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199(7):965-973
94. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis. 2008;197(12):1676-1684 (Pubitemid 351919631)
95. van Doornum GJ, Prins M, Juffermans LH, et al. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourinary Med. 1994;70(4):240-246 (Pubitemid 24252933)
96. Shvetsov YB, Hernandez BY, McDuffie K, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis. 2009;48(5):536-546
97. Aynaud O, Ionesco M, Barrasso R. Penile intraepithelial neoplasia. Specific clinical features correlate with histologic and virologic findings. Cancer. 1994;74(6):1762-1767 (Pubitemid 24301831)
98. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000;108(8):634-641 (Pubitemid 30336603)
99. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43(2):223-233